Simulations Plus Inc

NASDAQ:SLP

Earnings Call Analysis

Simulations Plus Sees 18% Revenue Growth and Strong Acquisitions Impact for 2025

In fiscal 2024, Simulations Plus achieved an impressive 18% revenue growth, with a notable 14% organic growth, surpassing guidance. Total revenue reached $70 million, while diluted EPS was $0.49. Significant contributions came from the Pro-ficiency acquisition, expected to generate between $15 million and $18 million in fiscal 2025. The company anticipates total revenue in the range of $90 million to $93 million, projecting a year-over-year growth of 28% to 33%. Adjusted EBITDA margin is guided between 31% and 33%, reflecting strategic goals toward long-term profitability.

Strong Performance in Fiscal 2024

The company reported a strong fiscal year 2024, with total revenues increasing by 18% to $70 million. Organic growth was robust, particularly in the service segment, which saw a 26% increase, contributing significantly to the overall revenue growth. The fourth quarter alone saw total revenue rise by 19% to $18.7 million, bolstered by a $2.3 million contribution from the Pro-ficiency acquisition.

Acquisitions Boosting Market Position

The completion and integration of the Pro-ficiency acquisition represent the largest in the company's history, doubling its total addressable market (TAM) to approximately $8 billion. Pro-ficiency is set to contribute between $15 million and $18 million to the upcoming fiscal year's revenues. The strategic acquisition has positioned the company as a leader in areas such as quantitative systems pharmacology, with overall growth attributed to this enhanced market opportunity.

Growth Guidance for Fiscal 2025

Looking ahead, the company anticipates total revenue for fiscal 2025 to range between $90 million and $93 million, indicating a year-over-year growth rate of 28% to 33%. They expect organic growth to remain consistent, projected between 10% and 15%, thanks to strong performances in both software and service segments. Furthermore, the adjusted diluted earnings per share (EPS) for fiscal 2025 is expected to be between $1.07 and $1.20, an increase compared to the prior year's diluted EPS of $0.49.

Segmentation: Software and Services Revenue

For fiscal 2024, software revenue accounted for 59% of total revenues, growing 12% compared to the previous year, while services revenue grew 26%, making up the remaining 41%. The company's software segments, particularly Cheminformatics and GastroPlus, continued to show resilience but experienced some fluctuation with organic growth dipping in the fourth quarter. This reflects challenges in the Asian market and project delays that may affect overall performance.

Adjustments in Financial Metrics

The company noted some fluctuation in its adjusted EBITDA, which for fiscal year 2024 was approximately $20.3 million but showed a decline from $20.6 million the previous year. The adjusted EBITDA margin is projected for fiscal 2025 to fall between 31% and 33%, with expectations for gradual improvement through the year as operational efficiency enhancements are rolled out. This strategy aims to align the company with its historical EBITDA margin target of 35% to 40%.

Operational Costs and Income Stability

The company's operating expenses have decreased from 66% of revenue to 53% year-over-year, showcasing improved cost management alongside successful integration of acquired entities. General and administrative expenses were notably reduced from 47% to 32% of revenue, primarily focusing on leveraging synergies from acquisitions. Net income for the fiscal year remained stable at $10 million, representing 14% of revenue, indicating solid financial health even amidst fluctuations in revenue contributions from acquisitions.

Market and Economic Environment

Despite current challenges in the pharmaceutical and biotech funding landscape, initial positive indicators for 2025 give rise to cautious optimism. This mixed environment suggests potential for greater client spending, which the company stands ready to capitalize on. The management has expressed readiness to adapt to changing market conditions, particularly as clients finalize their budget preparations for the upcoming year.

Conclusion

Overall, the company displayed impressive resilience and strategic foresight throughout fiscal 2024 and into 2025. Investors should focus on the anticipated revenue growth, operational efficiencies, and the benefits of strategic acquisitions, which are likely to drive performance and shareholder value in the years to come. With clear guidance and a focus on integration and market position, the company is well-prepared to navigate potential challenges in the evolving landscape.

Earnings Call Transcript 2024-Q4

[Operator]

Greetings, and welcome to the Simulations Plus Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

It is now my pleasure to introduce Lisa Fortuna from Financial Profiles. Ms. Fortuna, you may now begin.

[Lisa Fortuna]

Good afternoon, everyone. Welcome to the Simulations Plus Fourth Quarter and Fiscal 2024 Financial Results Conference Call. With me today are Shawn O'Connor, Chief Executive Officer; and Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus.

Please note that we updated our quarterly earnings presentation, which will serve as a supplement to today's prepared remarks. You can access the presentation on our Investor Relations website at www.simulations-plus.com. After management's commentary, we will open the call for questions.

As a reminder, the information discussed today may include forward-looking statements that involve risks and uncertainties. Words like believe, expect and anticipate refer to our best estimates as of this call, and actual future results could differ significantly from these statements. Further information on the company's risk factors is contained in the company's quarterly and annual reports and filed with the Securities and Exchange Commission.

With that, I'll turn the call over to Shawn. Please go ahead.

[Shawn O'Connor, executive]

Thank you, Lisa. Good afternoon, everyone, and thank you for joining our fourth quarter and fiscal 2024 conference call. Our team delivered strong results in 2024. Total revenue increased 18% year-over-year and 14% on an organic basis, excluding the fourth quarter contribution from Pro-ficiency. The organic growth rate was above the 10.5% growth rate we achieved in fiscal 2023, and at the high end of our guidance provided at the beginning of the fiscal year. Full year diluted EPS of $0.49 exceeded the high end of our guidance range of $0.46 to $0.48.

Turning to key highlights of the year. As an industry leader in biosimulation software tools, we continue to improve our competitive edge during fiscal 2024, with major upgrades across our platform supporting PBPK, PK/PD and drug discovery. GPx significantly enhanced our flagship GastroPlus, PBPK platform with advanced models, refined algorithms and integrated machine learning technology. GastroPlus greatly enriches the user experience with an intuitive interface, streamlined workflows and faster processing.

In May, we released Monolix Sweet 2024. This release included integrations, presets and other upgrades that make the software easier and faster to run, allowing scientists to spend less time on programming and more on exploring models and simulation results. In July, we released ADMET Predictor version 12, our machine learning cheminformatics platform in support of drug discovery. The release included enhanced models with greater predictive accuracy and expanded high-throughput pharmacometrics capabilities amongst other new features.

During fiscal year 2024, we continue to supplement our organic growth with strategic acquisition accomplishments. We completed the integration of our June 2023 acquisition at Immunetrics, the combined scientific resources and therapeutic area coverage positions us as a clear leader in the fast-growing area of quantitative systems pharmacology with 57% growth in fiscal year '24. This June, we acquired Pro-ficiency, the largest and most significant acquisition in our company history. The transaction doubles our TAM to $8 billion and significantly expands our market opportunity. This addition enhances our ability to support clients across clinical operations, affairs and commercialization. Our comprehensive suite of innovative solutions now spans the entire drug development continuum and uniquely positions us to drive growth and profitability.

Next, I'll spend a moment on the macro environment, which we realize is an area of particular focus for the financial community. Spending environment for pharma and biotech has been cost and funding constrained for a second fiscal year. Current leading indicators, including pharma budgets, clinical trial activity, funding activity and others provide a mixed bag of metrics for the next year that suggests a potentially improved environment compared to the last 2 years. We continue to observe a wide range of activity levels among our clients many who are engaged in their internal calendar year '25 budget preparation process.

Although we are encouraged by some positive initial budget discussion for 2025, we are entering the year with cautious optimism. Our guidance for fiscal year '25 is based upon current market conditions continuing, but we will be prepared to take advantage of any improvement in our client spending during the year.

Turning to our Software segment. Software revenue grew by 12% for fiscal year '24, 9% on an organic growth basis. Software revenue grew by 6% for the fourth quarter and decreased 6% on an organic growth basis. Cheminformatics business unit revenue grew 6% for the year and 1% in the fourth quarter. During fiscal year '24, we have grown the number of clients utilizing the AIDD module to 15 of our total installed base of 110 ADMET Predictor clients.

Physiologically-based pharmacokinetics, or PBPK business unit, revenue increased 7% for the year and decreased 8% in the fourth quarter. GastroPlus continues to grow well despite some renewal slippage in the fourth quarter and ongoing super growth in the Asian markets. Clinical pharmacology and pharmacometrics or our CPP business unit, revenue grew 18% for the fiscal year and 20% during the quarter. Monolix continues to increase its market share and displace its main competitor as the PK/PD platform of choice.

Revenue in our quantitative systems pharmacology or QST business unit grew 7% for the year, that decreased 67% for the quarter. As a reminder, quarterly results can be lumpy for QSP software based upon the high ticket price per license and a smaller pool of end users. Revenue in our adaptive learning and insights or Ali business unit was $1.1 million for the fourth quarter, generally in line with our expectations. Revenue in our Medical Communications, or MC business unit was $100,000 for the fourth quarter, also in line with our expectations.

Turning to our Services segment. Services revenue grew by 26% for fiscal year '24, 21% on an organic basis. Services revenue grew by 39% for the fourth quarter, 21% on an organic basis. We're pleased with this result given client cost constraint measures typically impact external service budgets as clients may eliminate budget work or delay execution in tighter funding environments. Performance was especially strong in CPP and QSP business units.

CPP business unit revenue was strong, up 19% for the fiscal year and up 28% in the fourth quarter. USP business unit revenue grew 57% for the year and 32% in the fourth quarter. PBPK business unit revenue decreased 5% for the fiscal year and 6% for the fourth quarter. We continue to encounter clients source data delays impacting the initiation of contracted projects in this space. Medical Communications revenue was $1.1 million in the fourth quarter. This contribution was less than anticipated due to higher revenue recognized in the quarter prior to our acquisition as well as some project timing delays.

Turning to an update on Pro-ficiency. As a reminder, Pro-ficiency provides experience in content simulation developed with AI technologies to enhance clinical trial success, data analytics and medical communications, both in the regulatory approval process as well as post-approval commercialization. Ultimately, these activities support increased confidence in regulatory success for our clients. In addition, proficiency meaningfully expands our customer return on investment by helping them achieve accelerated clinical trial cycles, reduce protocol deviations, reduced cost of clinical trial operations and improved market awareness. The combined product and service portfolio results in offerings across the pharma value chain.

Software offerings from Pro-ficiency include: Pro-ficiency performance management, an adaptive learning platform that uses lifeline simulation and detailed data tracking to increase recruitment, retention and protocol compliance during clinical trials. In simulations of complex real-world scenarios, learners are asked to make decisions and practice implementation of the trial protocol. The data generated provides insight into areas of the trial protocol that are unclear to health care practitioners, enabling clarification, further education prior to the start of clinical trials.

Panorama KOL Insights is a platform for key opinion leaders, research in the life science industry. It provides current information about influential industry leaders, which can be filtered by criteria, including, but not limited to, therapeutic expertise, professional affiliations and geographical location. We're pleased to report that the integration process is tracking ahead of plan across all fronts. As previously announced, we formed 2 business units, adaptive learning and insights to carry forward with our clinical simulations business, led by Jenny Rouse; and Medical Communications led by Murray Alper, who to address medical affairs and commercialization support for our clients.

On the sales and marketing front, our combined go-to-market strategies and lead generation are underway. We expect these efforts to contribute to business development opportunities. Together, our scientific and technological capabilities are expected to deliver enhanced products and services, which further benefit our claims. And additionally, we have integrated our back-office financial operational general and administrative organizations, which we will -- we expect will contribute to efficiencies and expense safety.

With that, I'll turn the call over to Will.

[William Frederick, executive]

Thank you, Shawn. To recap our strong fourth quarter performance, total revenue increased 19% to $18.7 million, including a $2.3 million contribution from Pro-ficiency. Software revenue increased 6%, representing 53% of total revenue and services revenue increased 39%, representing 40% of total revenue. Fiscal year total revenue increased 18% to $70 million. Software revenue increased 12%, representing 59% of total revenue and services revenue increased 26%, representing 41% of total revenue.

Turning to the software revenue contribution from our products for the quarter. GastroPlus was 49%, MonolixSuite was 17%, ADMET Predictor was 18% and other products were 15%. For the fiscal year, GastroPlus was 53%, MonolixSuite was 20% and ADMET Predictor was 18% and other products were 9%. For the year, our software customer renewal rate was 93% based on these and 84% based on accounts both increasing slightly compared to the prior year.

Average software revenue per customer for the year increased to $129,000. Shifting to our services revenue contribution by business unit for the quarter, CPP was 36%, QSP was 35%, PBPK was 17% and MC was 13%. For the fiscal year, PPP was 43%, QSP was 31%, PBPK was 23% and MC was 4%. Total services projects worked on during the quarter were 250. Year-end backlog decreased to $14.1 million, primarily impacted by 2 sources. First, there were some service contracts that slipped into September. And in the first 2 weeks of fiscal 2025, we've already closed more than $3 million of these. Second, we adjusted the backlog in the fourth quarter this year to remove open contracts that have been delayed, where there's still uncertainty regarding when the customers will resume the projects. As a result, anticipated revenue from backlog with 12 months increased to approximately 90% compared to 70% to 80% at the end of last year.

Total gross margin for the fiscal year was 62%, with software gross margin of 84% and gross margin of 30%. The year-over-year decline in gross margin was primarily due to the reclass of operating expenses with the reorganization of our internal structure, the full year expense impact from the Immunetrics acquisition last year and the additional expenses from the Pro-ficiency acquisition this year.

Turning to our consolidated income statement for the quarter. R&D expense was 10% of revenue compared to 7% last year. Sales and marketing expense was 14% of revenue compared to 11% last year. G&A expense was 19% of revenue compared to 63% last year. The G&A expense variance was primarily due to the reclass of expenses this year to cost of revenues collected in the reorganization of our internal structure mentioned at the beginning of the year. We also made a true-up of all international services related expenses for the year in the fourth quarter. G&A expense for the fourth quarter also included $1.7 million of transaction-related expenses for the acquisition of Pro-ficiency this year and included $2.5 million of transactions related expenses for the acquisition of Immunetrics last year.

The transaction expenses related to Immunetrics last year included a $1.6 million compensation expense. Total operating expenses were 43% of revenue compared to 80% last year primarily due to the reclass of expenses to cost of revenue this year offset by the addition of expenses related to Pro-ficiency this year.

Loss from operations was negative 6% of revenue compared to negative 2% last year, and income before income taxes was 5% of revenue compared to 0% last year. Other income was $2 million this quarter compared to $0.4 million last year primarily due to a decrease in the fair value of the Immunetrics earnout liability this year.

Net income for the fourth quarter was $0.8 million or 5% of revenue compared to $0.5 million or 3% of revenue last year. Diluted EPS was $0.04 compared to $0.03 last year. And adjusted diluted EPS, excluding the impact of transaction-related costs, were $0.06 compared to $0.18 last year. This year-over-year change was primarily driven by the transaction-related expense add-back to diluted EPS in Q4 last year being larger than the add back in Q4 this year. Fourth quarter adjusted EBITDA was $4.1 million compared to $4.9 million last year at 22% and 31% of revenue, respectively. We calculate adjusted EBITDA by adding back interest, taxes, depreciation and amortization stock-based compensation, gain or loss on currency exchange, any acquisition or financial transaction-related expenses and any asset impairment charges. The reconciliation of this non-GAAP metric to net income, the relevant GAAP metric is in our earnings release and on our website.

Income tax expense for the fourth quarter was less than $0.1 million compared to income tax benefit of $0.5 million last year. And our effective tax rate was 2% compared to 674% in the prior year period. As a reminder, we true up our annual income tax estimate in the fourth quarter each year which impacts the effective tax rate in the quarter. Turning to our consolidated income statement for the fiscal year. R&D expense was 8% of revenue equivalent to last year. Sales and marketing expense was 13% of revenue compared to 11% last year, primarily due to our increased investment in sales and marketing.

G&A expense was 32% of revenue, down from 47% last year. G&A expense for the year included $2.6 million of transaction-related expenses for the acquisition of Pro-ficiency this year, and included $3.3 million of transaction-related expenses for the acquisition of Immunetrics last year. Total operating expenses were 53% of revenue compared to 66% last year. Income from operations was 9% of revenue compared to 15% last year. And income before income taxes was 18% of revenue compared to 20% last year.

Other income was $6.3 million during the year compared to $3 million last year, primarily due to an increase in interest income and the previously mentioned decrease in the fair value of the Immunetrics earnout liability. Net income for the fiscal year was $10 million or 14% of revenue compared to $10 million or 17% of revenue last year. Diluted EPS was $0.49, equivalent to last year and adjusted diluted EPS, excluding the impact of transaction-related costs were $0.53 compared to $0.67 last year.

Adjusted diluted EPS was lower than expected primarily due to the lower transaction-related expense add back to diluted EPS in the fourth quarter.

Fiscal year adjusted EBITDA was $20.3 million compared to $20.6 million last year at 29% and 35% of revenue, respectively. Income tax expense for the fiscal year was $2.5 million compared to $1.7 million last year, and our effective tax rate was 20% compared to 15% last year. We expect our effective tax rate fiscal year 2025 to be in the range of 23% to 25%.

Turning to our balance sheet. We ended the year with $20 million in cash and investments. We remain well capitalized with no debt and strong free cash flow to execute our growth strategy.

I'll now turn the call back to Shawn.

[Shawn O'Connor, executive]

Thank you, Will. We're very pleased with our 2024 performance, and our results reflect strong execution in both our Software and Service segments. Also, the integration of the most significant acquisition in the history of our company is progressing ahead of our expectations.

Moving on to our outlook for fiscal 2025. Based upon current market conditions, our organic growth is expected to be in the range of 10% to 15%, consistent with fiscal year '24. In addition, the Pro-ficiency acquisition is expected to contribute $15 million to $18 million, consistent with the range we previously provided.

Our guidance for fiscal 2025 is as follows: Total revenue between $90 million and $93 million, year-over-year revenue growth in the range of 28% to 33%, software mix between 55% and 60%, adjusted EBITDA margin between 31% and 33%, adjusted diluted earnings per share of $1.07 to $1.20.

We're providing guidance on adjusted diluted EPS versus diluted EPS, consistent with guidance practices for our industry. For comparison purposes, our adjusted diluted EPS guidance translates to at or above our fiscal year '24 diluted EPS of $0.49. Of note, our guidance does not include the impact of any future acquisitions.

As a reminder, our first fiscal quarter is historically our lowest revenue quarter due to the seasonality of our revenue streams. As such, the EPS could dip below breakeven and a low diluted adjusted EPS will be above the diluted EPS level. We still expect some impact. We anticipate higher revenues in the remaining quarters of fiscal 2025, as we have had in the past, resulting in higher profitability in the remaining quarters of our fiscal year.

Our near-term priorities include completing the acquisition integration, expanding cross-selling opportunities, driving towards our historical adjusted EBITDA margin target of 35% to 40% and correspondingly profitability levels. We are well positioned to achieve our goals this year, and remain focused on executing our disciplined growth strategy to deliver long-term value to our stakeholders.

Thank you for your time today. With that, I'll turn the call over to the operator for your questions.

[Operator]

[Operator Instructions] Our first question is from Max Smock with William Blair.

[Max Smock, analyst]

Our first one was just hoping you can give an update on staffing and services. I recall that very low attrition rates in the business have been weighing on margins. So curious if this trend has continued over the last few months. And what your hiring plans look like in 2025, basically trying to get at when we can expect utilization to improve and how we should think about the cadence of margin progression in 2025?

[Shawn O'Connor, executive]

Yes. Thanks for the question. Yes, as we indicated last conference call, our back half profitability in Q3 and Q4 was impacted as we hired to our plan but attrition that we baked into that plan was much less than anticipated, and that has contributed to some pressure in terms of margins in the service business in the back half of the year continued into the fourth quarter. We have -- since this became more visible, adjusted our recruiting plans on a go-forward basis and anticipate that we'll get back in the line, if you will, with the matching of the capacity and revenue streams on the service side in the first half of fiscal '2025. So a little bit of pressure in the first half of next year, but I believe that improvement will be gradual and through the first half and into the second half, we should be back on track, and it's reflected in our guidance of 31% to 33% EBITDA margin and that improvement during the course of the year.

[Max Smock, analyst]

Great. That's really helpful. And then just one on proficiency in terms of its competitive moat. So given that we have seen a continuing trend and expectation for more trials to be run by CROs. And given that proficiency doesn't sell into CROs, do you see this as limiting the size of your business opportunity in the space?

[Shawn O'Connor, executive]

No, no. I mean the marketplace that they sell into is in support of pharma clients and their clinical trials in association with the CROs that are out there. We are complementary to their services, competitive to those that do offer this sort of comparable, if you will, training type of capabilities, but the Pro-ficiency offering is pretty unique in terms of both its training module development and the software platform that supports it in terms of its delivery and the impact on adherence to clinical trials. So clinical trial uptick in 2025 would be favorable indicator for the proficiency business, and it falls through in a marketplace alongside CROs and competition with some CROs, but that's the same marketplace that it's been selling into and succeed in the last number of years.

[Max Smock, analyst]

Great. And then lastly, just a quick modeling question. Sorry if you already said it, and I missed it. But how much did Immunetrics and Pro-ficiency contribute to total sales in Q4? And also, what is this breakdown in terms of software versus services, asking because based on the it seems like the inorganic contribution was much lower than we would have thought in the fourth quarter. So if this is the case, can you discuss the dynamics around this?

[Shawn O'Connor, executive]

Pro-ficiency's contribute came in a bit below the $3 million expectation that we had that came in at about $2.1 million, $2.2 million revenue in the second quarter, primarily in terms of the medical communications side, where our anticipation of how much of the project revenue, the service revenue from medical communications would be recognized in the quarter prior to our close of the transaction, obviously, don't pick up the revenue flow from those projects until close, which was mid-June time frame. So that recognition at the beginning of the quarter was a little bit greater than we anticipated.

And then secondly, yes, they were subject to some of the delays that we see across our service business in terms of some projects being pushed out. So 2.1 in terms of the Pro-ficiency contribution to the fourth quarter. And it does not change our expectation in terms of $15 million to $18 million contribution in there

Immunetrics fourth quarter contribution, I don't have a -- fourth quarter is not a acquisition revenue. They had fourth quarter contribution revenue in '23 as well as fourth quarter '24. And our integration of that business now is pretty well complete, and we're servicing those opportunities from the combined staff our 2 organizations. So don't have a breakout of that for the fourth quarter.

[Max Smock, analyst]

That was all really helpful. And just as you were talking at for 2025, kind of a similar question on Pro-ficiency. It seems like you're counting Pro-ficiency revenue as all inorganic, despite it kind of closing, like you said in the fourth quarter. So just hoping that you can help us bridge your organic versus inorganic growth expectations for next fiscal year and if you can, by both software and services.

[Shawn O'Connor, executive]

Yes, don't provide it other than our expectation that the software will be in the range of 55% to 60% of our total revenues. I don't have a breakout in terms of software versus services. But -- or, let's call it, SLP like business, everything except Pro-ficiency, our guidance is based upon the assumption of that organic growth will be in the 10% to 15% range, similar to our guidance for last year, fiscal year '24, which was 10% to 15% for which we came in at about 14% growth. And then 2025 proficiency contribution should be in that range of $15 million to $18 million of

[Operator]

Our next question is from Matt Hewitt with Craig-Hallum.

[Matthew Hewitt, analyst]

Maybe first up, could you help us bridge the gap on your EPS guidance for next year? Just trying to figure out significantly higher. And then I was modeled in -- the Street was model. I'm just trying to figure out what the doubt there?

[Shawn O'Connor, executive]

I think it's in the context of the 2 line items of adjusted diluted EPS versus diluted EPS -- we've added adjusted diluted EPS as it seems to be the commonality with our peers so that there could be some comparability. Will, do you want to provide some color in terms of the differential there?

[William Frederick, executive]

Sure. Thanks for the question, Matt. And I would refer to the reconciliations that we have in the press release. One of the things we did for FY '24 is we've got the reconciliation of adjusted EBITDA to net income. And for the most part, we've got typical exclusions there that we've communicated in the past. The adjusted diluted EPS to diluted EPS, we've really just taking transaction-related expenses as the adjustment. And based on the feedback we're getting from folks as well as sort of comparative in the industry, it made sense to standardize in FY '25, so for this next fiscal year to just have the reconciliation items that are in the adjusted EBITDA be the same adjustments that are going to be for the adjusted diluted EPS with the tax impact as well. So FY '24 was just an adjustment for transaction-related expenses. FY '25 will have a consistent approach with the way we do the adjusted EBITDA, just to simplify it.

[Matthew Hewitt, analyst]

That's helpful. But I guess, I was looking for -- I mean, are you expecting $5 million in acquisition-related expenses. There's a pretty big delta from where everybody was before on an adjusted basis to your new guidance. There was a -- that's a pretty big step up. And I'm just trying to figure out what is the bucket that you're seeing the big increase. I'm guessing it's M&A expenses, but I just want to make sure I'm thinking about this right.

[William Frederick, executive]

Yes. Right now, we don't have any M&A expenses assumed in the guidance, which it excludes any acquisitions. So to the extent that if you look through the EBITDA reconciliation, the big drivers there are depreciation and amortization expense and stock comp expense. I mean those combined were about $11 million, $12 million in FY '24 and will have an increase with the additional intangible amortization from the Pro-ficiency acquisitions. So that total probably goes to about $14 million, $15 million of adjustments.

[Matthew Hewitt, analyst]

Got it. All right. And then shifting gears, Shawn, if you could provide a little bit of an update on how the integration with Pro-ficiency, particularly on the sales and marketing efforts. Are those teams -- have they been fully trained at this point? What are the cross-selling pipeline is looking for?

[Shawn O'Connor, executive]

Yes. We've integrated the sales and marketing personnel that came to us in the acquisition for Pro-ficiency into our consolidated business development team, undertaken training dissemination of presentation of capabilities to bring people up to speed in terms of our new products and services that come into fold -- out in the marketplace, we've transitioned over the last couple of years. Our sell-through points and historically have been the discovery department for ADMET Predictor and then primarily the modeling and simulation organization on the clinical side.

Previous to this year, we invested time and effort in expanding to a third touch point, the clinical management teams that consolidated group of personnel that manage a drug program, of which the modeling and simulation representative has at that table. -- but extending our relationship into that area, I think has been one of the keys to supporting our pretty healthy service growth in a very challenged market environment, and that has been the result of identifying opportunities to impact positively a drug program that perhaps the modeling and simulation department has been already used up has been cut certainly cost constrained environment has made those budgets a little tighter. We opened ourselves up for our service business to be funded out of the clinical trial budget. And that, I think, is supported and wins in the sale of our success on our service side during a challenging time. Long would it enter into through Pro-ficiency's, we're now undertaking that same extension out to their touch points, which are the clinical operations team and the medical affairs team within our clients. And -- so first step in terms of engagement in the marketplace externally from the company. is to start extending those networks and building those relationships into those new budget opportunities that are available to us. And that's going very well. I mean we're 3 months into the close -- after the course of the acquisition, so it's a short window of time, but I think we're moving pretty well there.

[Operator]

Our next question is from David Larsen with BTIG.

[David Larsen, analyst]

Can you talk a little bit more about the software revenue growth on a year-over-year basis. I think I heard you say it was down 6% year-over-year organically. Is that correct? And how does that compare to your own internal expectations? And what was that internal growth rate or organic growth rate for the year, please?

[Shawn O'Connor, executive]

Yes. Will, can you just remind us of the specific growth rates on the software side as I flip through in mind, making sure I get it right. I mean, the growth rate was down in the fourth quarter but up 12% for the year, 9% organically, right?

[William Frederick, executive]

Yes. I mean, total revenue for the year, yes.

[Shawn O'Connor, executive]

So yes, fourth quarter revenues were down on the software side. Really, the challenge there has been -- was twofold. One, we did have a couple of renewal slippages out past August into the first quarter. But our real challenge has been in the Asian market. It's 1 of new issue. It's one that's really been in flux since COVID, quite frankly. And a particular focus for us as we move into fiscal year '25. We've been overgrowing, if you will, in our North America and European markets and compensating for that. But it's an area for improvement for us going forward.

[David Larsen, analyst]

Okay. And I think I see the software gross margin of around 72% in the fourth quarter. It's usually in the 90% range. So -- should we think about that as being like an unusual quarter because of some renewal timing and you'll get back up to that 90% range in 1Q of next year. So -- see that organic software revenue growth to back up starting in fiscal 1Q?

[Shawn O'Connor, executive]

Yes. Our software revenue margin is impacted. I don't know that it went all the way down into the 70s, I think was in the mid-80s. And so some impact there, as we indicated earlier, that the software side of the proficiency business is down towards 80-ish percent compared to our 90-plus percent in terms of our existing software or legacy software products. So some impact there. And the Pro-ficiency, overall profitability, both in terms of software, as I've just described and on the service side. We see -- means we're improving those as we move through the course of the year. We improved it tremendously through the acquisition in terms of rationalizing some of the overhead expenses of that business unit.

It starts in the fourth quarter and the start of fiscal year '25 with a profitability profile that on a percentage basis is a little less than our legacy model, if you will. The overall company EBITDA guidance of 31% to 33% underlying that on the legacy side, SLP, probably could have been up towards that goal that we set for ourselves at 35% to 40%, but Pro-ficiency impacts that in '25. We believe we -- in the longer term into '26, we'll get them in line with our profitability profile. But that will continue to improve to get to that level through the course of 2025. So on the software side, specifically back to your question, some impact from Pro-ficiency there, I think we'll gradually see some improvement as we go quarter-to-quarter through '25.

[David Larsen, analyst]

Great. One more quick one. I think the service gross margin you reported, am I seeing this correctly minus 4% in fiscal 4Q. And I'm assuming that, that's from Pro-ficiency, and it's my understanding that Pro-ficiency is very much tied to like the clinical trial activity, basically training the folks at the site on how to basically implement the clinical trial that's in line with basically the trial master file. So can you maybe just talk about perhaps, I don't know, the mix of clinical trials that you're supporting, for example, if there's more obesity health-related clinical trials, if you're seeing a slowdown in like perhaps gene therapies because the funding environment, I would think would be very good. Just any more color there. And I think you hired a couple of scientists last quarter -- are they being -- like are they selling -- just any more color on that, you expect a lift to that service gross margin?

[Shawn O'Connor, executive]

Yes. Two-part answer. I'll talk to the proficiency side of your question. And then, Will, maybe you can talk to the fourth quarter margin with some reclass issues there. Pro-ficiency in terms of, yes, supportive clinical trial activity on the simulation side as its primary focus, business driver, if you will. No specialty in terms of singular therapeutic areas. They're portfolio of past projects spans most all therapeutic areas tends to be more valued in difficult complex clinical trial protocols where obviously a more aggressive comprehensive training ahead of its initiation benefits protocol adherence more significantly. But there's no therapeutic area sort of concentration in terms of their portfolio of activities. Will, do you want to talk about the margin?

[William Frederick, executive]

Sure. And I can answer this for the software analyst services. So Q4 certainly has some true-ups that we do when we look at the -- on an annual basis when we go through the audit process. 72% you mentioned for software for the quarter and Q4. That was primarily due to just the Immunetrics software impact coming in a bit lighter. But as Shawn mentioned, mid-80s or where we would expect to see that going forward. I used to be in the 85 to 90 range, and we mentioned there'd be some decline there. On the services side, for Q4, we did look through the year. I think I mentioned it during the call. There was an adjustment that we made, it was about $2.5 million. Looking through the year for international efforts that we have with employees and services group, they're all worked through a professional employer organization or a PEO. We reclassed those from G&A expense for the year into services. We did that in Q4.

So that, again, looking forward, the total year is 30% services margin as we continue going forward and leveraging the efficiency business and our business, looking for upsides with billable utilization focus that 30% to 40% range is where we'd be targeting.

[Operator]

Our next question is from Scott Schoenhaus with KeyBanc Capital Markets.

[Scott Schoenhaus, analyst]

I wanted to touch on the 10% to 15% organic growth outlined for next year. As we sit here today, you said your guidance contemplates levels from what we're seeing here today, which is clearly depressed you had the same kind of guidance -- organic revenue guidance last year. So maybe walk us through what's expected or built into the low end of that range and the top end of that range? And maybe specifically also on like where you think the biotech end market is expected to be for next year?

[Shawn O'Connor, executive]

Yes. We're all trying to throw that dirt and read the tea leaves in terms of we are only moving forward, and we certainly see some positive things I saw the Thermo CEO spoke very positively today of market opportunity into 2025. And we see a lot of positive too. Our discussions of late in terms of clients budgetary processes that phenomena of our industry in which we've got a few dollars left to spend this year. We lose it if we don't spend it by the end of the calendar year. Some great discussions taking place right now, and I want to be optimistic, but I'm also conscious. We've seen upticks in funding that have been short-lived and pulled back. And therefore, our approach here in terms of guidance for '25 is pretty -- is conservatively set based upon okay, the market as it is today. The range of 10% to 15% organic growth. We came in higher end of that range this year. I've got confidence in our organization, we've executed well. in a challenging market over the last 2-year window of time and would be confident in terms of our ability to perform at the high end of that range, but guidance being what it is, we'll take a conservative approach and carry forward our 10% to 15% from last year. But poised, if current market conditions do run on the uptick and start to improve, this fourth quarter of the calendar year or into '25 that we should be able to support and grow with that growth as well into next year. But certainly, at this point in time but prudent that we take a conservative approach to setting our guidance for next year.

[Scott Schoenhaus, analyst]

So I'm assuming you're meaning that you have very little assumptions of a return or reacceleration of the biotech end market, given all that commentary is that

[Shawn O'Connor, executive]

No. I have hoped for, but from a guidance sort of perspective, let's start to accrue before we count happen.

[Scott Schoenhaus, analyst]

And then as a follow-up, I think you mentioned in your prepared remarks, Shawn, that you saw some slip in renewals on the GastroPlus. Can you provide maybe more color on that contract? Was it a large pharma? What was the decision there to not renew or a pushout of the renewal -- can you just give us more color on what happened there on the GastroPlus side?

[Shawn O'Connor, executive]

Yes. The pushouts it's not a nonrenewal decision. It's get the paperwork through and get the documentation purchase order and not get that all done by August 31 to our funky fiscal year here. August, a lot of people are on vacation in a just it's not an excuse, but it sometimes is often difficult to get things closed. I mean the only challengeable one in the mix there is that in the fourth quarter, we did have a renewal situation where we had a specific client that acquired a second company during the course of the year and, in fact, then as well closed one of their sites. And so that was a situation where we had 3 renewals come up. The original company, the acquired company, and within that original company, their license configuration was site-based. And so in that situation, which is when you look back over our history in terms of the differential between mid-90 renewal rates on software and 100%, what is that difference? I mean it's either companies going bankrupt and departing the landscape or consolidation. And so we had one of those in the fourth quarter results. The slippage ones are timing and aren't takeaways of our book of business, if you will. It's only those acquisition scenarios that can be troublesome.

[Operator]

Our next question is from François Brisebois with Oppenheimer & Company.

[François Brisebois, analyst]

Just two here. I was just wondering if you can give us a little more explanation or color around that TAM doubling that you talk about. It's not necessarily a biosimulation play, but with Pro-ficiency here, how do you get to a doubling of the TAM? And then I know you're still getting this acquisition integrated, but any other color on more M&A? Or is it just one step at a time. This is a big acquisition. Let's get this one figured out for the time being?

[Shawn O'Connor, executive]

Sure, Frank. Yes, I mean, the TAM incremental with the Pro-ficiency of the incremental $4 billion is pretty evenly split between the 2 markets, our assessment of what is the market for the training activity in clinical trial space, an estimate of what is spent in that area across clinical trials, all phases, all therapies, et cetera. Of course, specifically, the training aspect of a clinical trial. And on the MEDCOM side, their marketplace is twofold. It's more predominant in the regulatory process, preapproval process and in part as well sourced and medical communications agency work that's done post approval in the commercialization process for a new drug market entry. And their business is skewed a little bit towards the regulatory process. And so therefore, we've calculated that TAM in that same disproportionate towards the regulatory market activity there.

Acquisitions are a continuous process in terms of working in the landscape and following companies that are on your radar and adding and deleting those that come and go. We've certainly devoted resources to the integration process of our most recent acquisition. But our strategy is unchanged in terms of supplementing organic growth with acquisitions. I'd say, yes, we're going to take a little bit of a breath and in terms of the vigor there, but it is not on the shelf and not active at any point in time and should an opportunity arise that fits our criteria there was certainly regarded at that opportunity. And we will continue to do acquisitions. So we've gone from a we used to get questions, when are you going to do the next acquisition because you haven't done -- We've done one in each of the last 2 years. Our cadence is, I think, good there. No guidance that we'll do one in 2025. But certainly, the underlying activity that could lead to that is active.

[Operator]

Our next question is from Costine David with Citizens JMP.

[Unknown Analyst]

Shawn, this -- correct me if I'm wrong, this is the time of the year, you typically would look to flex price. I'm just wondering how that would look going forward in terms of how much price you would look to increase? And how would that compare to last year?

[Shawn O'Connor, executive]

Yes, it is sort of our adjusted price list time frame of the year. And our approach this year around was somewhat similar to last year. If the outcome was similar to last year. Historically, that price increase can be 5%-plus sort of level. Typically, you don't yielding 100% of that large clients or in particular market segments, you're looking to discount to gain footholds. 2 years ago, not last year, not fiscal year '23 by fiscal year '22, we're a little bit more aggressive. It was a start on, I'll call it, peak of inflationary macro environment and what not, came back down in fiscal year '24 and as we enter fiscal year '25, relatively comparable to last year.

[Unknown Analyst]

Great And then I guess just one follow-up on operating expenses. For the past few years, sales and R&D growth has kind of occurred at a clip that exceeds sales growth. Are you going to start to see a little bit more leverage in fiscal '25 on those line items?

[Shawn O'Connor, executive]

Yes. We -- true. We've invested in sales and marketing and R&D. Keep in mind that this past year, the reclass where we initiated the beginning in the first quarter, at the beginning of the year and reclassing costs out of G&A into gross margin. Some of that's gone into sales and marketing and R&D overhead costs that follow the people that are working in those line items, if you will. But certainly, incremental to that, we've made investments that I think are paying off. When I look to the execution and success we've had in double-digit growth and stepping up our growth in fiscal year '24, that in good part is due to those business development resources that we have -- we've built and gives us the confidence when we make an acquisition, micoproficiency acquisition that we have the infrastructure on the business development side to leverage those products and services, new products and services going forward.

So we will get more leverage, but I think we are already getting the leverage out of the business development side. And on the R&D side, a great year with delivery of significant releases across all areas of our software platform that has been delivered by that R&D group, which is supplemented with the benefit of some type collaborations with large pharma clients as well as the regulatory environment. You may have noted that we've had a recent FDA have another FDA grant collaboration we're engaged. So overall, I think we made some investments there in R&D and sales and marketing. I think we're getting the benefit of it and that benefit will accrue going forward. That said, overall, we're particularly focused in terms of getting the business back to historical profitability levels at 35% plus adjusted EBITDA level and I feel good in programs that we've initiated that will move us into that direction in '25. And I think we'll have the potential to accrue benefit beyond that as well.

[Operator]

There are no further questions at this time. I'd like to hand the floor back over to Mr. Shawn O'Connor.

[Shawn O'Connor, executive]

Thanks again, everyone, for joining our call today and your interest in SLP. I'll note as well for those in terms of clearing on market conditions and we're wrapping up our participation in 2 of the most significant conferences in our -- at least on the biosimulation side. One is wrapping up today and another occurs in a couple of weeks. The AATS Farm 360 Conference and the ACOP conference next month, 2 significant conferences for us and look forward to the activity and the type generates.

Also on the horizon or conference attendance by myself at Stephen's conference and a BTI investor conference virtual conference, I believe it is next month, and hope to see many of you there. With that, we'll close off the call. And again, thanks for joining us today.

[Operator]

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.